Maxine Waters
Showing 1–2 of 2 transcripts.
- Milken Institute16 min
A Conversation with Maxine Waters, US Representative, California
The Congressional Task Force on Alzheimer's Disease, led by a Congresswoman whose advocacy is driven by personal family tragedy, has secured bipartisan funding that raised research allocations from $586 million in 2015 to a $2.65 billion request for 2020. This legislative push aims to achieve a cure or effective treatment by 2025 while addressing critical caregiver burdens and correcting public misconceptions about memory loss through expanded testing and outreach to underrepresented populations. With significant support from 130 lawmakers and the private sector, the initiative focuses on drug pricing reforms and integrated medical strategies to prevent the disease from bankrupting the national healthcare system.
- Milken Institute1h 5m
The Future of Brain Health
Maxine Waters, Michael Clowden, Meg Terrell, Dr. Ruth Benka, Dr. Marie Bernard, Dr. Rod Hockman, Nora Super, Dr. Rudy Tanzi
Congresswoman Maxine Waters secured bipartisan backing from 130 legislators for a proposed $2.65 billion Alzheimer's research budget, aiming to meet the 2025 national goal of a cure while addressing the projected bankruptcy of the U.S. healthcare system. Parallel scientific advances, including Biogen's Aducanumab and new insights into viral links and sleep-based protein clearance, are being matched by systemic reforms to shift 50% of care to home settings and address the disproportionate burden on female caregivers. Despite these strides, experts emphasize that reducing reliance on acute hospitalization and mitigating risks through lifestyle interventions like blood pressure control and social engagement remain critical to curbing the disease's demographic and economic impact.